HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sato, Y. Articles by Satoh, K. Search for Related Content PubMed PubMed Citation Articles by Sato, Y. Articles by Satoh, K. Related Collections Related Article

Risedronate therapy for prevention of hip fracture after stroke in elderly women

From the Department of Neurology (Dr. Sato), Mitate Hospital, Tagawa; Department of Sport Medicine (Dr. Iwamoto), Keio University School of Medicine, Tokyo; and Departments of Rehabilitation Medicine (Dr. Kanoko) and Vascular Biology (Dr. Satoh), Hirosaki University School of Medicine, Hirosaki, Japan.

Address correspondence and reprint requests to Dr. Yoshihiro Sato, Department of Neurology, Mitate Hospital, 3237 Yugeta, Tagawa 826–0041, Japan; e-mail: y-sato{at}ktarn.or.jp

Background: There is a high incidence of hip fractures in patients with hemiplegic stroke. Bone mineral density (BMD) is decreased in the hemiplegic side in patients after stroke, correlating with the degree of paralysis and of hypovitaminosis D.

Objective: To evaluate the efficacy of risedronate in reducing the severity of osteoporosis and in decreasing the risk of hip fractures in elderly women following an acute stroke.

Methods: This was a 12-month, randomized, double blind, placebo-controlled trial. In a prospective study of stroke patients, 187 patients received a daily dose of 2.5 mg risedronate for 12 months, and the remaining 187 received placebo. Incidence of hip fracture was compared between the two groups at the endpoint of the study.

Results: Seven patients sustained hip fractures on the hemiplegic side in the placebo group, and one hip fracture occurred in the risedronate group (p = 0.0360; OR = 7.0). BMD increased by 1.5% and decreased by 4.9% in the risedronate group and placebo group (p < 0.0001). Urinary deoxypyridinoline, a bone resorption marker, decreased by 53.4% in the risedronate group and increased by 35.8% in the placebo group.

Conclusion: Treatment with risedronate increases bone mineral density in elderly women following an acute stroke and prevents hip fractures.

Related Article

March 8 Highlights
Neurology 2005 64: 772-773. [Full Text] [PDF]

This article has been cited by other articles:

				A. Qaseem, V. Snow, P. Shekelle, R. Hopkins Jr., M. A. Forciea, D. K. Owens, and for the Clinical Efficacy Assessment Subcommittee Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med, September 16, 2008; 149(6): 404 - 415. [Abstract] [Full Text] [PDF]

				R. L. Gardner, F. Harris, E. Vittinghoff, and S. R. Cummings The Risk of Fracture Following Hospitalization in Older Women and Men Arch Intern Med, August 11, 2008; 168(15): 1671 - 1677. [Abstract] [Full Text] [PDF]

				J. Marsden, L. M. Gibson, C. E. Lightbody, A. K. Sharma, M. Siddiqi, and C. Watkins Can early onset bone loss be effectively managed in post-stroke patients? An integrative review of the evidence Age Ageing, March 1, 2008; 37(2): 142 - 150. [Abstract] [Full Text] [PDF]

				C. MacLean, S. Newberry, M. Maglione, M. McMahon, V. Ranganath, M. Suttorp, W. Mojica, M. Timmer, A. Alexander, M. McNamara, et al. Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis Ann Intern Med, February 5, 2008; 148(3): 197 - 213. [Abstract] [Full Text] [PDF]

				P.K. Myint, K.E.S. Poole, and E.A. Warburton Hip fractures after stroke and their prevention QJM, September 1, 2007; 100(9): 539 - 545. [Abstract] [Full Text] [PDF]

				K. E.S. Poole, N. Loveridge, C. M. Rose, E. A. Warburton, and J. Reeve A Single Infusion of Zoledronate Prevents Bone Loss After Stroke Stroke, May 1, 2007; 38(5): 1519 - 1525. [Abstract] [Full Text] [PDF]

				J. M. Halbekath, S. Schenk, A. von Maxen, G. Meyer, and I. Muhlhauser Risedronate for the Prevention of Hip Fractures: Concern About Validity of Trials Arch Intern Med, March 12, 2007; 167(5): 513 - 514. [Full Text] [PDF]

				N. J. Bainbridge, M. W. J. Davie, and M. J. Haddaway Bone loss after stroke over 52 weeks at os calcis: influence of sex, mobility and relation to bone density at other sites Age Ageing, March 1, 2006; 35(2): 127 - 132. [Abstract] [Full Text] [PDF]

				K. E.S. Poole, E. A. Warburton, J. Reeve, Y. Sato, J. Iwamoto, T. Kanoko, and K. Satoh Risedronate therapy for prevention of hip fracture after stroke in elderly women Neurology, November 8, 2005; 65(9): 1513 - 1514. [Full Text] [PDF]

				Y. Sato, J. Iwamoto, T. Kanoko, and K. Satoh Risedronate Sodium Therapy for Prevention of Hip Fracture in Men 65 Years or Older After Stroke Arch Intern Med, August 8, 2005; 165(15): 1743 - 1748. [Abstract] [Full Text] [PDF]

Correspondence: